The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2798-2806

  Place, Andrew E ^a   Suh, Nanjoo ^a   Williams, Charlotte R ^a   Risingsong, Renee ^a   Honda, Tadashi ^b   Honda, Yukiko ^b   Gribble, Gordon W ^b   Leesnitzer, Lisa M ^c   Stimmel, Julie B ^c   Willson, Timothy M ^c   Rosen, Evan ^d   Sporn, Michael B ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b Dartmouth College   (United States)

^c GLAXOSMITHKLINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OYL]IMIDAZOLE; 2 CHLORO 5 NITROBENZANILIDE; 6 [1 (5,6,7,8 TETRAHYDRO 3,5,5,8,8 PENTAMETHYL 2 NAPHTHYL)CYCLOPROPYL]NICOTINIC ACID; ILX 7553; IMIDAZOLE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; TRITERPENOID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FIBROBLAST; GROWTH INHIBITION; IC 50; LEUKEMIA CELL; MALE; MEASUREMENT; MELANOMA CELL; MOUSE; NONHUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD36; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINE, TUMOR; CELL SEPARATION; CHOLECALCIFEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLASTS; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; INFLAMMATION; INHIBITORY CONCENTRATION 50; MICE; MODELS, CHEMICAL; MONOCYTES; NEOPLASMS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OLEANOLIC ACID; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; U937 CELLS;

EID: 12444337488     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Nishino, H., Nishino, A., Takayasu, J., Hasegawa, T., Iwashima, A., Hirabayashi, K., Iwata, S., and Shibata, S. Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-acetate by some oleanane-type triterpenoid compounds. Cancer Res., 48: 5210-5215, 1988.
2. Singh, G. B., Singh, S., Bani, S., Gupta, B. D., and Banerjee, S. K. Anti-inflammatory activity of oleanolic acid in rats and mice. J. Pharm. Pharmacol., 44: 456-458, 1992.
3. Huang, M. T., Ho, C. T., Wang, Z. Y., Ferraro, T., Lou, Y. R., Stauber, K., Ma, W., Georgiadis, C., Laskin, J. D., and Conney, A. H. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res., 54: 701-708, 1994.
4. Tang, W., and Eishandbrand, G. Chinese Drugs of Plant Origin. New York: Springer-Verlag, 1992.
5. Honda, T., Rounds, B. V., Gribble, G. W., Suh, N., Wang, Y., and Sporn, M. B. Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg. Med. Chem. Lett., 8: 2711-2714, 1998.
6. Honda, T., Gribble, G. W., Suh, N., Finlay, H. J., Rounds, B. V., Bore, L., Favaloro, F. G., Jr., Wang, Y., and Sporn, M. B. Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem., 43: 1866-1877, 2000.
7. Honda, T., Rounds, B. V., Bore. L., Finlay, H. J., Favaloro, F. G., Jr., Suh, N., Wang, Y., Sporn, M. B., and Gribble, G. W. Synthetic oleanane and ursane triterpenoids with modified rings A and C: a series of highly active inhibitors of nitric oxide production in mouse macrophages. J. Med. Chem., 43: 4233-4246, 2000.
8. Suh, N., Wang, Y., Honda, T., Gribble. G. W., Dmitrovsky, E., Hickey, W. F., Maue, R. A., Place, A. E., Porter, D. M., Spinella, M. J., Williams, C. R., Wu, G., Dannenberg, A. J., Flanders, K. C., Letterio, J. J., Mangelsdorf, D. J., Nathan, C. F., Nguyen, L., Porter, W. W., Ren, R. F., Roberts, A. B., Roche, N. S., Subbaramaiah, K., and Sporn, M. B. A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res., 59: 336-341, 1999.
9. Ito, Y., Pandey, P., Place, A., Sporn, M. B., Gribble, G. W., Honda, T., Kharbanda, S., and Kufe, D. The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth. Differ., 11: 261-267, 2000.
10. Ito, Y., Pandey, P., Sporn, M. B., Datta, R., Kharbanda, S., and Kufe, D. The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mecha- nism. Mol. Pharmacol., 59: 1094-1099, 2001.
11. Stadheim, T. A., Suh, N., Ganju, N., Sporn, M. B., and Eastman, A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J. Biol. Chem., 277: 16448-16455, 2002.
12. Pedersen, I. M., Kitada, S., Schimmer, A., Kim, Y., Zapata, J. M., Charboneau, L., Rassenti, L., Andreeff, M., Bennett, F., Sporn, M.B., Liotta, L. D., Kipps, T. J., and Reed, J. C. The triterpenoid CDDO induces apoptosis in refractory CLL B cells. Blood, 100: 2965-2972, 2002.
13. Konopleva, M., Tsao, T., Ruvolo, P., Stiouf, I., Estrov, Z., Leysath, C. E., Zhao, S., Harris, D., Chang, S., Jackson, C. E., Munsell, M., Suh, N., Gribble, G., Honda, T., May, W. S., Sporn, M. B., and Andreeff, M. Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood, 99: 326-335, 2002.
14. Wang, Y., Porter, W. W., Suh, N., Honda, T., Gribble. G. W., Leesnitzer, L. M., Plunket, K. D., Mangelsdorf, D. J., Blanchard, S. G., Willson, T. M., and Sporn, M. B. A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor γ. Mol. Endocrinol., 14: 1550-1556, 2000.
15. Honda, T., Honda, Y., Favaloro, F. G., Gribble, G. W., Suh, N., Place, A. E., Rendi, M. H., and Sporn, M. B. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg. Med. Chem. Lett., 12: 1027-1030, 2002.
16. Sporn, M. B., and Roberts, A. B. Peptide growth factors and inflammation, tissue repair, and cancer. J. Clin. Investig., 78: 329-332, 1986.
17. Ohshima, H., and Bartsch, H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res., 305: 253-264, 1994.
18. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
19. Lala, P. K., and Chakraborty, C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol., 2: 149-156, 2001.
20. Muller-Decker, K., Neufang, G., Berger, I., Neumann, M., Marks, F., and Furstenberger, G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc. Natl. Acad. Sci. USA, 99: 12483-12488, 2002.
21. Bharti, A., and Aggarwal, B. Nuclear factor-κβ and cancer: its role in prevention and therapy. Biochem. Pharmacol., 64: 883-888, 2002.
22. Rosen, E. D., Hsu, C. H., Wang, X., Sakai, S., Freeman, M. W., Gonzalez, F. J., and Spiegelman, B. M. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev., 16: 22-26, 2002.
23. Suh, N., Honda, T., Finlay, H. J., Barchowsky, A., Williams, C., Benoit, N. E., Xie, Q. W., Nathan, C., Gribble, G. W., and Sporn, M. B. Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages. Cancer Res., 58: 717-723, 1998.
24. Arnaout, M. A. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood, 75: 1037-1050, 1990,
25. Hayden, J. M., Brachova, L., Higgins, K., Obermiller, L., Sevanian, A., Khandrika, S., and Reaven, P. D. Induction of monocyte differentiation and foam cell formation in vitro by 7-ketocholesterol. J. Lipid. Res., 43: 26-35, 2002.
26. Prieto, J., Eklund, A., and Patarroyo, M. Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell. Immunol., 156: 191-211, 1994.
27. Lehmann, J. M., Jong, L., Fanjul, A., Cameron, J. F., Lu, X. P., Haefner, P., Dawson, M. I., and Pfahl, M. Retinoids selective for retinoid X receptor response pathways. Science (Wash. DC), 258: 1944-1946, 1992.
28. Boehm, M. F., Zhang, L., Zhi, L., McClurg, M. R., Berger, E., Wagoner, M., Mais, D. E., Suto, C. M., Davies, J. A., and Heyman, R. A. Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells. J. Med. Chem., 38: 3146-3155, 1995.
29. Zhou, J. Y., Norman, A. W., Lubbert, M., Collins, E. D., Uskokovic, M. R., and Koeffler, H. P. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization. Blood, 74: 82-93, 1989.
30. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA, 87: 3929-3932, 1990.
31. Huang, J. T., Welch, J. S., Ricote, M., Binder, C. J., Willson, T. M., Kelly, C., Witztum, J. L., Funk. C. D., Conrad, D., and Glass, C. K. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature (Lond.), 400: 378-382, 1999.
32. Willson, T. M., Brown, P. J., Sternbach, D. D., and Henke, B. R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 43: 527-550, 2000.
33. Teicher, B. A. (ed.). Tumor Models in Cancer Research. Humana Press, Totowa, NJ 2002.
34. Tontonoz, P., Nagy, L., Alvarez, J. G., Thomazy, V. A., and Evans, R. M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell, 93: 241-252, 1998.
35. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., and Chambon, P. The nuclear receptor superfamily: the second decade. Cell, 83: 835-839, 1995.
36. 3 and its fluorinated analogues. Cancer Res., 44: 5624-5628, 1984.
37. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
38. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in Apc Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
39. Kawamori, T., Rao, C. V., Seibert, K., and Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412, 1998.
40. Kitamura, T., Kawamori, T., Uchiya, N., Itoh, M., Noda, T., Matsuura, M., Sugimura, T., and Wakabayashi, K. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis (Lond.), 23: 1463-1466, 2002.
41. Suh, N., Roberts, A. B., Reffey, S., Miyazono, K., Itoh, S., Ten Dijke, P., Heiss, E. H., Place, A. E., Risingsong, R., Williams, C. R., Honda, T., Gribble, G. W., and Sporn, M. B. Synthetic tripterpenoids enhance TGF-β signaling. Cancer Res., 63: 1371-1376, 2003.
42. Derynck, R., Akhurst, R. J., and Balmain, A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet., 29: 117-129, 2001.
43. Wakefield, L. M., and Roberts, A. B. TGF-β signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev., 12: 22-29, 2002.
44. Schuster, N., and Krieglstein, K. Mechanisms of TGF-β-mediated apoptosis. Cell Tissue Res., 307: 1-14, 2002.
45. Ten Dijke, P., Goumans, M, J., Itoh, F., and Itoh, S. Regulation of cell proliferation by Smad proteins. J. Cell. Physiol., 191: 1-16, 2002.
46. Yanagisawa, J., Yanagi, Y., Masuhiro, Y., Suzawa, M., Watanabe, M., Kashiwagi, K., Toriyabe, T., Kawabata, M., Miyazono, K., and Kato, S. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science (Wash. DC), 283: 1317-1321, 1999.
47. Yanagi, Y., Suzawa, M., Kawabata, M., Miyazono, K., Yanagisawa, J., and Kato, S. Positive and negative modulation of vitamin D receptor function by transforming growth factor-β signaling through smad proteins. J. Biol. Chem., 274: 12971-12974, 1999.
48. 3 and transforming growth factor-β signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J. Biol. Chem., 276: 15741-15746, 2001.
49. Matsuda, T., Yamamoto, T., Muraguchi, A., and Saatcioglu, F. Cross-talk between transforming growth factor-β and estrogen receptor signaling through Smad3. J. Biol. Chem., 276: 42908-42914, 2001.
50. Kang, H. Y., Lin, H. K., Hu, Y. C., Yeh, S., Huang, K. E., and Chang, C. From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells. Proc. Natl. Acad, Sci. USA, 98: 3018-3023, 2001.
51. Kang, H. Y., Huang, K. E., Chang, S. Y., Ma, W. L., Lin, W. J., and Chang, C. Differential modulation of androgen receptor-mediated transactivation by Smad3 and tumor suppressor Smad4. J. Biol. Chem., 277: 43749-43756, 2002.
52. Song, C. Z., Tian, X., and Gelehrter, T. D. Glucocorticoid receptor inhibits transforming growth factor-β signaling by directly targeting the transcriptional activation function of Smad3. Proc. Natl. Acad. Sci. USA, 96: 11776-11781, 1999.
53. Nichols, J. S., Parks, D. J., Consler, T. G., and Blanchard, S. G. Development of a scintillation proximity assay for peroxisome proliferator-activated receptor γ ligand binding domain. Anal. Biochem., 257: 112-119, 1998.